Lancashire and South Cumbria
Formulary
Formulary
4 Central nervous system
04-02-03 Lithium
Due to differences in bioavailability prescribing should be by brand name. For new patients Priadel is recommended. Lithium carbonate 200mg is equivalent to Lithium citrate 509mg.
There are significant interactions with lithium, see BNF.
| Lithium Carbonate Camcolit® |
|
Formulary
|
Modified-release tablets 400mg Treatment and prophylaxis of mania, bipolar disorder and recurrent depression. Aggressive or self-mutilating behaviour. |
 LSCMMG: Shared care guideline |
|
| Lithium Carbonate Priadel® |
|
Formulary
|
M/R tablets 200mg, 400mg Treatment and prophylaxis of mania, bipolar disorder and recurrent depression. Aggressive or self-mutilating behaviour. |
|
LSCMMG: Shared care guideline |
|
|
| Lithium Citrate Priadel® |
|
Formulary
|
Liquid 520mg/5mL Treatment and prophylaxis of mania, bipolar disorder and recurrent depression. Aggressive or self-mutilating behaviour. |
|
LSCMMG: Shared care guideline |
|
|
Links
- LMMG SCG Lithium July 2019
- LMMG SCG Lithium July2019
- LSCMMG: Shared care guideline
- LSCMMG: Shared care guideline
- LSCMMG: Shared care guideline
- MHRA Drug SAfety Update April 2018: Valproate medicines (Epilim, Depakote): contraindicated in women and girls of childbearing potential unless conditions of Pregnancy Prevention Programme are met
- MHRA Drug Safety Update April 2019: Valproate medicines and serious harms in pregnancy: new Annual Risk Acknowledgement Form and clinical guidance from professional bodies to support compliance with the Pregnancy Prevention Programme
- MHRA Drug Safety Update April2018: Valproate medicines (Epilim, Depakote): contraindicated in women and girls of childbearing potential unless conditions of Pregnancy Prevention Programme are met
- MHRA Drug Safety update Feb 2016 : Valproate and of risk of abnormal pregnancy outcomes: new communication materials
- MHRA Drug Safety Update Feb 2016: Valproate and of risk of abnormal pregnancy outcomes: new communication materials
- MHRA Drug Safety Update Sept 2018: Valproate Pregnancy Prevention Programme: actions required now from GPs, specialists, and dispensers
- MHRA Drug Safety Update Sept 2018: Valproate Pregnancy Prevention Programme: actions required now from GPs, specialists, and dispensers
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Antiepileptic drugs: updated advice on switching between different manufacturers products
- MHRA: Antiepileptics: risk of suicidal thoughts and behaviour
- MHRA: Antiepileptics: risk of suicidal thoughts and behaviour
- MHRA: Antiepileptics: risk of suicidal thoughts and behaviour
- MHRA: Antiepileptics: risk of suicidal thoughts and behaviour
- MHRA: Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression
- MHRA: Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions
- MHRA: Full pack dispensing of valproate-containing medicines
- MHRA: Valproate use in men: as a precaution, men and their partners should use effective contraception
- MHRA: Valproate use in men: as a precaution, men and their partners should use effective contraception
- NICE CG103: Delirium: prevention, diagnosis and management
- NICE CG155: Psychosis and schizophrenia in children and young people: recognition and management
- NICE CG178 Psychosis and schizophrenia in adults: prevention and management
- NICE CG185 Bipolar disorder: assessment and managemen
- NICE CG185: Bipolar disorder: assessment and management
- NICE CG192: Antenatal and postnatal mental health: clinical management and service guidance
- UHMB Lithium therapy risk assessment form
- UHMB Lithium therapy risk assessment form
- UHMB lithium therpay risk assessment form